Recombinant Human Erythropoietin in Anaemic Patients with End-Stage Renal Disease
Journal of Medical Sciences · 01.06.2009 · 8 (2) · 26-29
DOI: 10.51984/x0q8ha11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Sciences, online erschienen am 01.06.2009. Verfasst von Almahdi Wardami Alamen und 3 weiteren Autor:innen.
Abstract (Originalsprache)
The effect of erythropoietin (EPO) on the anaemia of end-stage renal disease was investigated in 76 transfusion-dependent haemodialysis patients. EPO was administered intravenously in a dose of 50μ/kg, 3 times a week for 12 weeks. The haematocrit had risen from 18.7 ± 1-9 to 26.6 ± 3.8 on day 84. Fifty-eight patients (76.3%) responded with an increase in haematocrit of ≥6. Complications included hypertension (21.1%), iron deficiency (18.4%), thrombosis of vascular access (7.9%). This relatively low rate response could be accounted for by differences in the treatment policy. It remains to be seen whether the standard protocol of EPO use in renal failure would improve the response.
Zitieren
APA
Alamen, A. W., Ahmed, M. G., Milad, M. H., & Bukhari, F. D. J. (2009). Recombinant Human Erythropoietin in Anaemic Patients with End-Stage Renal Disease. Journal of Medical Sciences, 8(2), 26-29. https://doi.org/10.51984/x0q8ha11
Vancouver
Alamen AW, Ahmed MG, Milad MH, Bukhari FDJ. Recombinant Human Erythropoietin in Anaemic Patients with End-Stage Renal Disease. Journal of Medical Sciences. 2009;8(2):26-29. doi:10.51984/x0q8ha11
BibTeX
@article{Alamen2009,
author = {Alamen, Almahdi Wardami and Ahmed, Mutwakil G. and Milad, Mahmoud H. and Bukhari, Fathi D. J.},
title = {Recombinant Human Erythropoietin in Anaemic Patients with End-Stage Renal Disease},
journal = {Journal of Medical Sciences},
year = {2009},
volume = {8},
number = {2},
pages = {26--29},
doi = {10.51984/x0q8ha11}
}
EUVIMED